Syngene International Reports Strong Q2 FY27 Performance With 13% Sequential Revenue Growth And Improved EBITDA Margins

Syngene International Ltd reported a strong performance in the second quarter of fiscal year 2027, with revenue from operations growing by 13% sequentially to ₹833 crore. The company's operating EBITDA margin also improved by 6 percentage points, reaching 18%. For the first half of fiscal year 2027, Syngene recorded revenue from operations of ₹1,569 crore and an operating EBITDA margin of 15%.

Managing Director and CEO Siddharth Mittal attributed the sequential revenue growth to positive traction in the CDMO business. The company also announced the appointment of Dr Jayashree Aiyar as Chief Scientific Officer, who will take on additional responsibility for Discovery Services. Syngene secured its first manufacturing agreement for the Bayview biologics facility in the U.S. and continued to secure additional manufacturing contracts for clinical supplies from its Bengaluru biologics manufacturing facility.

Brief written by urgent.news from Free Press Journal's own syndicated text. Machine-written — may contain errors; check the original before relying on it.